Soleno Therapeutics, Inc.
SLNO
$48.12
-$0.91-1.85%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 98.68M | 32.66M | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 98.68M | 32.66M | -- | -- | -- |
| Cost of Revenue | 1.84M | 696.00K | -- | -- | -- |
| Gross Profit | 96.84M | 31.96M | -- | -- | -- |
| SG&A Expenses | 128.55M | 144.00M | 126.65M | 105.86M | 72.70M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 182.95M | 218.98M | 204.13M | 184.43M | 138.47M |
| Operating Income | -84.27M | -186.32M | -204.13M | -184.43M | -138.47M |
| Income Before Tax | -78.45M | -181.08M | -198.23M | -175.85M | -131.16M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -78.45 | -181.08 | -198.23 | -175.85 | -131.16 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -78.45M | -181.08M | -198.23M | -175.85M | -131.16M |
| EBIT | -84.27M | -186.32M | -204.13M | -184.43M | -138.47M |
| EBITDA | -82.26M | -184.32M | -202.13M | -182.44M | -136.50M |
| EPS Basic | -1.83 | -4.15 | -4.62 | -4.26 | -3.31 |
| Normalized Basic EPS | -1.08 | -2.52 | -2.80 | -2.61 | -2.01 |
| EPS Diluted | -1.85 | -4.15 | -4.62 | -4.26 | -3.31 |
| Normalized Diluted EPS | -1.09 | -2.52 | -2.80 | -2.61 | -2.01 |
| Average Basic Shares Outstanding | 193.92M | 182.47M | 170.61M | 160.64M | 151.16M |
| Average Diluted Shares Outstanding | 195.51M | 182.47M | 170.61M | 160.64M | 151.16M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |